Results 1 to 10 of about 16,072 (215)

Nanoemulsified Butenafine for Enhanced Performance against Experimental Cutaneous Leishmaniasis [PDF]

Journal of Immunology Research, 2021
The production of ergosterol lipid involves the activity of different enzymes and is a crucial event for the Leishmania membrane homeostasis. Such enzymes can be blocked by azoles and allylamines drugs, such as the antifungal butenafine chloride.
Adriana Bezerra-Souza, Jéssica A. Jesus, Márcia D. Laurenti, Aikaterini Lalatsa, Dolores R. Serrano, Luiz Felipe D. Passero   +5 more
doaj   +8 more sources

Immunomodulation From Moderate Exercise Promotes Control of Experimental Cutaneous Leishmaniasis [PDF]

Frontiers in Cellular and Infection Microbiology, 2019
Physical exercise has been described as an important tool in the prevention and treatment of numerous diseases as it promotes a range of responses and adaptations in several biological systems, including the immune system.
Rodrigo Terra, Pedro J. F. Alves, Ana K. C. Lima, Shayane M. R. Gomes, Luciana S. Rodrigues, Verônica P. Salerno, Silvia A. G. Da-Silva, Patricia M. L. Dutra   +7 more
doaj   +5 more sources

Efficacy of Paromomycin-Chloroquine Combination Therapy in Experimental Cutaneous Leishmaniasis. [PDF]

Antimicrob Agents Chemother, 2017
The 4-aminoquinoline chloroquine (CQ) is clinically used in combination with doxycycline to cure chronic Q fever, as it enhances the activity of the antibiotic against the causative bacterium Coxiella burnetii residing within macrophage phagolysosomes ...
Wijnant GJ, Van Bocxlaer K, Yardley V, Murdan S, Croft SL.   +4 more
europepmc   +8 more sources

Activity of Amphotericin B-Loaded Chitosan Nanoparticles against Experimental Cutaneous Leishmaniasis [PDF]

Molecules, 2020
Chitosan nanoparticles have gained attention as drug delivery systems (DDS) in the medical field as they are both biodegradable and biocompatible with reported antimicrobial and anti-leishmanial activities.
Alaa Riezk, Katrien Van Bocxlaer, Vanessa Yardley, Sudaxshina Murdan, Simon L. Croft   +4 more
doaj   +8 more sources

Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis. [PDF]

Int J Parasitol Drugs Drug Resist, 2019
Drugs for Neglected Diseases initiative (DNDi) has identified three chemical lead series, the nitroimidazoles, benzoxaboroles and aminopyrazoles, as innovative treatments for visceral leishmaniasis. The leads discovered using phenotypic screening, were optimised following disease- and compound-specific criteria.
Van Bocxlaer K, Caridha D, Black C, Vesely B, Leed S, Sciotti RJ, Wijnant GJ, Yardley V, Braillard S, Mowbray CE, Ioset JR, Croft SL.   +11 more
europepmc   +5 more sources

Microemulsion based on methyl 3,4,5-trihydroxybenzoate for the topical treatment of cutaneous leishmaniasis: an in vivo assay [PDF]

Acta Amazonica, 2023
Cutaneous leishmaniasis, caused by protozoa of the genus Leishmania, presents diverse clinical manifestations, and current therapeutic options have limitations, including long treatment periods, potential hospitalization, and excessive pain during ...
Thiago de Jesus BACHA, Bruno Bezerra JENSEN, Daniele de Carvalho RODRIGUES, Messe Elmer Torres da SILVA, Amanda Oliveira ARAÚJO, Katia Solange Cardoso Rodrigues dos Santos GERALDI, Robson Cabral VALADÃO, Francimeire Gomes PINHEIRO, Antonia Maria Ramos FRANCO   +8 more
doaj   +1 more source

Transcription of toll-like receptors 2, 3, 4 and 9, FoxP3 and Th17 cytokines in a susceptible experimental model of canine Leishmania infantum infection [PDF]

, 2015
Canine leishmaniosis (CanL) due to Leishmania infantum is a chronic zoonotic systemic disease resulting from complex interactions between protozoa and the canine immune system.
A Ives, A Rodriguez, A Rodriguez-Cortes, A Rodriguez-Cortes, A Rodriguez-Cortes, AB Reis, AK House, AK Rai, Alhelí Rodríguez-Cortés, AM Elassad, BL Travi, C Gallego, C Gonzalez-Lombana, C Maia, C Maia, C Riera, CE O'Neil, CF Alves, CR Engwerda, D Menezes-Souza, D Sacks, D Strauss-Ayali, DA Vargas-Inchaustegui, Damer P. Blake, E Bourreau, F Chappuis, FF Tuon, FF Tuon, G Baneth, GA Cezario, GD Melo, GK Katara, GM Santos-Gomes, H Kumar, IR Peters, J Alvar, J Liese, J Moreno, J Sano, JF Flandin, JM Ehrchen, Jordi Alberola, K Ghosh, K Wolk, Karin Allenspach, KL Silva, L Solano-Gallego, L Solano-Gallego, Laia Solano-Gallego, LM Melo, LP Carvalho, MA Almeida, MG Pitta, MJ de Veer, MJ Rica-Capela, MM Figueiredo, MM Figueiredo, MS Nascimento, N Peters, O Courtenay, O Francino, OA Garden, OR Rodrigues, P Desjeux, P Holzmuller, P Kropf, R Kumar, S Lopez Kostka, S Nylen, S Schmitz, S Tiwananthagorn, S Tolouei, SH Wood, Shazia Hosein, T Korn, TM Castilho, VL da Matta, VS Boaventura, VS Raman, Y Belkaid, Yara M. Traub-Csekö, ZK Peng   +81 more
core   +13 more sources

Development of a biocompatible polymeric chitosan system for the release of compounds with leishmanicidal activity

Materials & Design, 2021
Leishmaniasis is a tropical disease caused by parasites of the genus Leishmania spp; it presents different clinical manifestations, of which cutaneous leishmaniasis is the most common form, and it is endemic in more than 70 countries worldwide. Only four
Jorge Higuita-Castro, Iván D. Vélez, Diana M. Escobar, Javier Murillo, Tatiana Pineda, Victoria Ospina, Sara M. Robledo   +6 more
doaj   +1 more source

Pathogen- and Host-Directed Antileishmanial Effects Mediated by Polyhexanide (PHMB) [PDF]

, 2015
BACKGROUND:Cutaneous leishmaniasis (CL) is a neglected tropical disease caused by protozoan parasites of the genus Leishmania. CL causes enormous suffering in many countries worldwide. There is no licensed vaccine against CL, and the chemotherapy options
A Ponte-Sucre, AA Momeni, AF Jebran, AM Carmona-Ribeiro, B Castillo, B Monge-Maillo, Bianca Röger, BLF Schamber-Reis, CM Choi, D Gerit, D Lockwood, DP Eiras, DS Lima-Junior, E Moreno, E Von Stebut, FB Chekeni, G Bringmann, G Carneiro, G Carneiro, G Morizot, G Müller, G Rusciano, G Walls, H Yin, Heidrun Moll, I Arevalo, IJ Gonzalez-Leal, J Alvar, JR Ramírez-Pineda, K Kaehn, Kantaraja Chindera, KT Andrews, L Novo, L-I McCall, Liam Good, Lorenz Meinel, LP O’Malley, M Ghosh, M Yamamoto, M-A Hartley, Maria Cecilia Amstalden, Martina Schultheis, Mary Ann McDowell, MJ Allen, MN Jabbour, MS Bailey, N Datta, Nina Hecht, Nor Fadhilah Kamaruzzaman, R Firdessa, R Hurdayal, Rebuma Firdessa, S Das, S Gupta, S Sundar, S Wessels, Salah A Ben, SK Samal, T Hirsch, T Ikeda, T Lang, T Sato, Tessa Lühmann, Tobias A. Oelschlaeger   +63 more
core   +12 more sources

Activity of paromomycin against Leishmania amazonensis: Direct correlation between susceptibility in vitro and the treatment outcome in vivo

International Journal for Parasitology: Drugs and Drug Resistance, 2020
Paromomycin is an aminoglycoside antibiotic approved in 2006 for the treatment of visceral leishmaniasis caused by Leishmania donovani in Southeast Asia.
Elizabeth M. Coser, Bianca A. Ferreira, Nilson Branco, Edite H. Yamashiro-Kanashiro, José Angelo L. Lindoso, Adriano C. Coelho   +5 more
doaj   +1 more source